Adherence of Stalevo, Entacapone and Levodopa
Information source: South Glasgow University Hospitals NHS Trust
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Parkinson's Disease
Phase: N/A
Status: Completed
Sponsored by: South Glasgow University Hospitals NHS Trust Official(s) and/or principal investigator(s):
Donald G Grosset, MBChB, MD, Principal Investigator, Affiliation: Unaffiliated
Summary
To test if combining two antiparkinson drugs into a single tablet improves accuracy of
medicine intake by the patient.
To test if patients with Parkinson's disease who take medicines at regular time intervals
have smoother symptom control.
Clinical Details
Official title: Study of Adherence of Stalevo, Entacapone and Levodopa
Study design: Other
Eligibility
Minimum age: 18 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients diagnosed with Parkinson's disease aged between 18 and 85 years fulfilling UK
Brain Bank criteria.
- Current levodopa therapy prescribed on a regular basis three or more times per day but
requiring entacapone because of 'wearing off'
- Able to manipulate electronic monitoring bottles and complete questionnaires
Exclusion Criteria:
- Current use of compliance aid such that study participation would be detrimental to
patient's adherence
- Pregnancy or breast feeding
- Excess alcohol (over 21 units per week for women and 28 units for men)
- Mini mental state examination of less than 26.
- Severe depression (Geriatric depression score over 20)
Locations and Contacts
Southern General Hospital, Glasgow, Scotland G51 4TF, United Kingdom
Additional Information
Starting date: April 2005
Ending date: July 2006
Last updated: May 22, 2008
|
